SLC2A1 and cancer: For decades, HIF-1 and its downstream effectors such as LDHA, GLUT1 and PDK1, which mediates tumour metabolic adaptation, have been long recognized as potential targets for cancer drug due to their profound impacts in cancer progression61, 62, 63, 64, 65, 66.